MannKind Corporation (MNKD) Shares Slide -0.81%

MannKind Corporation (MNKD) : During the past 4 weeks, traders have been relatively bearish on MannKind Corporation (MNKD), hence the stock is down -18.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.75% relative to the S&P 500. The 4-week change in the price of the stock is -16.1% and the stock has fallen -0.81% in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.4% and the 50-Day Moving Average is 5.42%. MannKind Corp. has dropped 26.67% during the last 3-month period . Year-to-Date the stock performance stands at -31.72%.


MannKind Corporation (NASDAQ:MNKD): stock turned positive on Friday. Though the stock opened at $0.97, the bulls momentum made the stock top out at $1 level for the day. The stock recorded a low of $0.9538 and closed the trading day at $0.99, in the green by 2.05%. The total traded volume for the day was 2,002,289. The stock had closed at $0.9701 in the previous days trading.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.